Janux Therapeutics, Inc. (JANX)

Janux Therapeutics' stock price has experienced significant fluctuations over the past six months, declining by approximately 45.26% over this period and by 46.1% over the past 90 days. Key events include Q3 2025 earnings exceeding expectations on November 6, 2025. An update on Phase 1 data for JANX007 in mCRPC on December 2, 2025, led to a significant stock drop due to concerns about differentiation. On December 23, 2025, Janux provided a program update on its ongoing Phase 1 study evaluating JANX008. Insider selling activity was noted on January 2, 2026. Janux announced an exclusive worldwide license agreement with Bristol Myers Squibb on January 22, 2026, causing the stock to rise pre-market.

As a clinical-stage biopharmaceutical company with products still in development, there is no readily available information indicating demand seasonality for Janux Therapeutics' products or services. Demand for its future products will likely be driven by clinical efficacy, regulatory approvals, and market adoption rather than seasonal patterns.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer patients, operating within the biotechnology sector and health technology industry. The company uses its technology platforms to engineer drug candidates that selectively modulate T cells to fight cancer without systemic safety issues. Its major product candidates in clinical trials include JANX007, a PSMA-TRACTr in Phase 1 for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-TRACTr in Phase 1 for multiple solid cancers. The company's development pipeline also includes discovery-stage products and a strategic research collaboration agreement with Merck Sharp & Dohme Corp.

Janux Therapeutics, Inc. is headquartered in San Diego, California. The company engages in collaborations that include potential for global commercialization.

Janux Therapeutics holds a "Moderate Buy" consensus rating from analysts, with an average score of 2.67. MarketBeat ranked Janux higher than 60% of companies in the medical sector. However, the company's stock has underperformed the US Biotechs industry and the broader US Market over the past year. The update on JANX007 Phase 1 data on December 2, 2025, likely had a negative impact on the company's reputation. Insider selling by executives on January 2, 2026, could be perceived negatively. The collaboration with Bristol Myers Squibb on January 22, 2026, is a positive development that would enhance the company's reputation.

Janux Therapeutics, Inc. has a substantial institutional ownership base, with 351 institutional owners and shareholders holding a total of 70,852,916 shares. Major institutional owners include RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Janus Henderson Group plc, BlackRock, Inc., FMR LLC, Paradigm BioCapital International Fund Ltd., Paradigm Biocapital Advisors LP, Adage Capital Management, L.P., Adage Capital Partners, L.P., and The Vanguard Group, Inc.